The global digestive and intestinal remedies market was valued at $18,250.0 million in 2021, and is projected to reach $26,243.4 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.
Gastrointestinal conditions are disorders of digestive system, an extensive and complex system that breaks down food in order to absorb water and extract nutrients, minerals and vitamins for the body’s use, while removing unabsorbed waste. Symptoms of digestive disorders vary from condition to condition. Some of the common symptoms for most gastrointestinal problems include abdominal discomfort, unintentional weight loss, acid reflux, diarrhea, constipation, and fecal incontinence. Prevalence of these symptoms increases demand for various options for treatment. For instance, according to data by the Centers for Disease Control and Prevention in 2018, the estimated number of adults diagnosed with ulcers was 14.8 million, which is a 5.9% of total population. Moreover, in 2018, the number of visits to physician offices with diseases of digestive system as a primary diagnosis was about 37.2 million. The symptoms for this disease can be well treated by medicines such as laxatives, antacids, acidifying agents, and may also need use of digestive enzymes as a part of treatment.
The global digestive and intestinal remedies market is anticipated to show significant growth during the forecast period, owing to increase in gastrointestinal disorders, changes in natural food habits, and high demand for related over-the-counter products. Furthermore, increase in prevalence of digestive diseases such as inflammatory bowel disease, constipation, irritable bowel syndrome, and gastroesophageal reflux illness and increase in healthcare expenditure considerably contribute toward the market growth. However, increase in consumption of supplementary food products and availability of alternative therapies for gastrointestinal diseases negatively impact the market growth. In addition, economic growth in emerging markets offers lucrative opportunities for growth of the market.
The global digestive and intestinal remedies market is segmented on the basis of type, age group, distribution channel, and region. By type, the market is classified into digestive medicines and gastrointestinal agents & remedies. Furthermore, the digestive medicines segment is sub-classified into online and offline. The gastrointestinal agents & remedies segment is sub-classified into online and offline. By age group, the market is classified into pediatric and adult. By distribution channel, it is classified into online and offline. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Abbott Laboratories, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, Jiangzhong Pharmaceutical Co Ltd, Johnson & Johnson, Menarini Group, Merck KGaA, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Reckitt Benckiser Group Plc, Sanofi S.A., Taisho Pharmaceutical Holdings Co Ltd, and Takeda Pharmaceutical Company Limited.
Gastrointestinal conditions are disorders of digestive system, an extensive and complex system that breaks down food in order to absorb water and extract nutrients, minerals and vitamins for the body’s use, while removing unabsorbed waste. Symptoms of digestive disorders vary from condition to condition. Some of the common symptoms for most gastrointestinal problems include abdominal discomfort, unintentional weight loss, acid reflux, diarrhea, constipation, and fecal incontinence. Prevalence of these symptoms increases demand for various options for treatment. For instance, according to data by the Centers for Disease Control and Prevention in 2018, the estimated number of adults diagnosed with ulcers was 14.8 million, which is a 5.9% of total population. Moreover, in 2018, the number of visits to physician offices with diseases of digestive system as a primary diagnosis was about 37.2 million. The symptoms for this disease can be well treated by medicines such as laxatives, antacids, acidifying agents, and may also need use of digestive enzymes as a part of treatment.
The global digestive and intestinal remedies market is anticipated to show significant growth during the forecast period, owing to increase in gastrointestinal disorders, changes in natural food habits, and high demand for related over-the-counter products. Furthermore, increase in prevalence of digestive diseases such as inflammatory bowel disease, constipation, irritable bowel syndrome, and gastroesophageal reflux illness and increase in healthcare expenditure considerably contribute toward the market growth. However, increase in consumption of supplementary food products and availability of alternative therapies for gastrointestinal diseases negatively impact the market growth. In addition, economic growth in emerging markets offers lucrative opportunities for growth of the market.
The global digestive and intestinal remedies market is segmented on the basis of type, age group, distribution channel, and region. By type, the market is classified into digestive medicines and gastrointestinal agents & remedies. Furthermore, the digestive medicines segment is sub-classified into online and offline. The gastrointestinal agents & remedies segment is sub-classified into online and offline. By age group, the market is classified into pediatric and adult. By distribution channel, it is classified into online and offline. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Abbott Laboratories, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline Plc, Jiangzhong Pharmaceutical Co Ltd, Johnson & Johnson, Menarini Group, Merck KGaA, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Reckitt Benckiser Group Plc, Sanofi S.A., Taisho Pharmaceutical Holdings Co Ltd, and Takeda Pharmaceutical Company Limited.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the digestive & intestinal remedies market analysis from 2021 to 2031 to identify the prevailing digestive & intestinal remedies market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the digestive & intestinal remedies market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global digestive & intestinal remedies market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Digestive Medicines
- Gastrointestinal Agents and Remedies
By Age Group
- Pediatirc
- Adult
By Distribution Channel
- Online
- Offline
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- Bausch Health Companies Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Glaxosmithkline plc
- Jiangzhong Pharmaceutical Co Ltd
- Johnson & Johnson
- Menarini Group
- Merck KGaA
- Pfizer Inc.
- Prestige Consumer Healthcare Inc.
- Procter & Gamble Company
- Reckitt Benckiser Group plc
- Sanofi S.A.
- Taisho Pharmaceutical Holdings Co Ltd
- Takeda Pharmaceutical Company Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: DIGESTIVE & INTESTINAL REMEDIES MARKET, BY TYPE
CHAPTER 5: DIGESTIVE & INTESTINAL REMEDIES MARKET, BY AGE GROUP
CHAPTER 6: DIGESTIVE & INTESTINAL REMEDIES MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: DIGESTIVE & INTESTINAL REMEDIES MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Digestive and Intestinal Remedies Market," the digestive and intestinal remedies market size was valued at $18.25 billion in 2021, and is estimated to reach $26.24 billion by 2031, growing at a CAGR of 3.6% from 2022 to 2031.Gastrointestinal (GI) diseases are among the most common digestive problems that commonly manifest as diarrhea, abdominal pain, abdominal distention, gastrointestinal bleeding, intestinal obstruction, malabsorption, or malnutrition. Moreover, infectious diarrheal diseases are an important cause of morbidity and mortality in childhood. These symptoms of GI disease can be treated by use of over-the-counter medicines that include antacids, proton pump inhibitors, histamine blockers, and similar products. These medicines are readily available at pharmacy stores in localities or on online commerce platforms.
The global digestive and intestinal remedies market forecast is anticipated to show significant growth during the forecast period, owing to increase in gastrointestinal disorders, changes in natural food habits, and high demand for related over-the-counter products. Furthermore, increase in prevalence of digestive diseases such as inflammatory bowel disease, constipation, irritable bowel syndrome, and gastroesophageal reflux illness and increase in healthcare expenditure considerably contribute toward the market growth. However, increase in consumption of supplementary food products and availability of alternative therapies for gastrointestinal diseases negatively impact the market growth. In addition, economic growth in emerging markets offers lucrative opportunities for growth of the market.
Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The situation of COVID-19 has varied outcome when related to vaccinations. There is an emerging gap in the economic recovery between high-income and low and middle income countries. After the pandemic severely disrupted global trade, the world is witnessing a robust rebound, which is helping with the recovery in the year 2021. Trade contributes to speeding up economic recovery from the pandemic by providing sustained foreign demand for exports and ensuring the availability of imported intermediate products and services. The COVID-19 pandemic affected the digestive and intestinal remedies industry in a fairly positive way, like various other pharmaceutical industries were effected. According to the data of research study named “COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist”, that was published in Digestive Diseases Journal in March 2021, the digestive system may be affected by the SARS-CoV-2 virus, and those with the pre-existing disease are at greatest risk of adverse outcomes. Moreover, according to the research data of American Journal of Physiology named “The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19”, in August 2020, COVID-19 cases with gastrointestinal symptoms are more likely to be complicated by liver injury and acute respiratory distress syndrome (ARDS), if these are not treated in time, coma and circulatory failure may occur.
Overall, the COVID-19 pandemic had a fairly positive impact on the digestive and intestinal remedies industry owing to the increased research and developments activities about the role of gastrointestinal tract in the COVID-19 pandemic. Moreover, increasing prevalence of some gastrointestinal diseases also helped the market to boost the growth amidst the pandemic situation.
By type, the digestive and intestinal remedies market is segmented into digestive medicines and gastrointestinal agents & remedies. The gastrointestinal agents & remedies segment is expected to dominate the market during the forecast period, owing to increase in use of gastrointestinal agents such as antacids protectives and adsorbents. Moreover, the digestive medicines segment is expected to register a CAGR of 4.6% during the forecast period, owing to the trends such as new product launches and various product approvals by market players.
By age group, the digestive and intestinal remedies market is segmented into pediatric and adult. The adult segment is expected to dominate the market during the forecast period, owing to increase in prevalence of gastrointestinal diseases among the adult population and rise in geriatric population. Moreover, the adult segment is also expected to register a CAGR of 3.7% during the forecast period, owing to the rise in incidences of gastrointestinal problems among adults for which over-the-counter drugs can be used.
By distribution channel, the digestive and intestinal remedies market is segmented into online and offline. The offline segment is expected to dominate the market during the forecast period, owing to increase in number of offline pharmacy stores available for gastrointestinal medicines. Moreover, the online segment is expected to register a CAGR of 4.4% during the forecast period, owing to surge in preference of online platforms for gastrointestinal drugs.
Europe accounted for the largest digestive and intestinal remedies market share of revenue in 2021, and is anticipated to maintain its dominance from 2021 to 2031, owing to presence of large patient population, strong presence of key players, ease of drug availability, well developed healthcare infrastructure, higher number of research, development, & innovation activities, and higher adoption of advanced therapeutics. However, Asia-Pacific is expected to grow at the highest CAGR of 4.6%, owing to the digestive and intestinal remedies market trends like increase in number of target population and rise in awareness related to different gastrointestinal disorders. In addition, increase in healthcare expenditure offers a lucrative opportunity for the growth of digestive and intestinal remedies market size.
Key Findings of the Study
- By type, the gastrointestinal agents & remedies segment accounted for major share of the digestive and intestinal remedies market in 2021.
- By age group, the adult segment is anticipated to grow with the highest CAGR during the forecast period.
- By distribution channel, the offline segment occupied major share of the digestive and intestinal remedies market in 2021.
- By region, Asia-Pacific is anticipated to grow at the highest rate during the forecast period, followed by LAMEA as per the digestive and intestinal remedies market analysis.
Companies Mentioned
- Abbott Laboratories
- Bausch Health Companies Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- GlaxoSmithKline plc
- Jiangzhong Pharmaceutical Co Ltd
- Johnson & Johnson
- Menarini Group
- Merck Kgaa
- Pfizer Inc.
- Prestige Consumer Healthcare Inc.
- Procter & Gamble Company
- Reckitt Benckiser Group plc
- Sanofi S.A.
- Taisho Pharmaceutical Holdings Co Ltd
- Takeda Pharmaceutical Company Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 162 |
| Published | July 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 18250 million |
| Forecasted Market Value ( USD | $ 26243.4 million |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
